Armas Pharmaceuticals Adds Four Generic Injectables As First Launches of 2020

Monday, January 20, 2020 Drug News
Email Print This Page Comment bookmark
Font : A-A+

MANALAPAN, N.J., Jan. 20, 2020 /PRNewswire/ -- Armas Pharmaceuticals Inc. (Armas), has begun the new year with launches of four generic injectables: Caffeine Citrate, Docetaxel, Gemcitabine and Verapamil HCI. These products are now a part of Armas' consistently growing product line, bringing their portfolio count to eleven. The following are sizes available on each of the new products:

Caffeine Citrate Injection (the generic equivalent of Hikma's, CAFCIT®), available in 60mg/3mL; has an approximate market size of $4M, annually.

Docetaxel Injection (the generic equivalent of Sanofi's, Taxotere®), available in 20mg/1mL, 80mg/4mL and 160mg/8mL; has an approximate market size of $45M, annually.

Gemcitabine Injection (the generic equivalent of Eli Lilly's, Gemzar®), available in 200mg/5.26mL, 1G/26.3mL and 2G/52.6mL; has an approximate market size of $25M, annually.

Verapamil HCI Injection (the generic equivalent of Pfizer's, Calan®), available in 5mg/2mL and 10mg/4mL; has an approximate market size of $31M, annually.

"Building off the incredible success Armas saw in our first full year, we are excited to be adding these items to our growing product line," said Joe Niemi, Chief Operating Officer, Armas Pharmaceuticals. "From the start, Armas' mission was to bring affordability to healthcare and we continue to work towards that goal by partnering with our customers and bringing down the overall cost to the patient."

About Armas Pharmaceuticals, Inc.Armas Pharmaceuticals is a generic pharmaceutical company delivering an ever-growing portfolio of high-quality products that provide convenience, affordability and consistency. Through the development of strong partnerships and industry relationships, Armas maintains this pipeline of products with customer and patient satisfaction in mind. Headquartered in Manalapan, New Jersey, Armas Pharmaceuticals is always open to new partnership opportunities and ways to offer our customers the best products at affordable prices. For more information, please visit ArmasPharmaceuticals.com.

Contact:Jenifer Arabia, Director, Sales & MarketingArmas Pharmaceuticals732-637-1717232671@email4pr.com

Cision View original content:http://www.prnewswire.com/news-releases/armas-pharmaceuticals-adds-four-generic-injectables-as-first-launches-of-2020-300989083.html

SOURCE Armas Pharmaceuticals



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Diabetes Premium Membership Benefits

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store